Product nameAnti-PON1 antibody
See all PON1 primary antibodies
DescriptionRabbit polyclonal to PON1
Tested applicationsSuitable for: IHC-P, WBmore details
Species reactivityReacts with: Mouse, Human
Recombinant full length protein corresponding to Human PON1 aa 1-355.
MAKLIALTLLGMGLALFRNHQSSYQTRLNALREVQPVELPNCNLVKGIET GSEDLEILPNGLAFISSGLKYPGIKSFNPNSPGKILLMDLNEEDPTVLEL GITGSKFDVSSFNPHGISTFTDEDNAMYLLVVNHPDAKSTVELFKFQEEE KSLLHLKTIRHKLLPNLNDIVAVGPEHFYGTNDHYFLDPYLQSWEMYLGL AWSYVVYYSPSEVRVVAEGFDFANGINISPDGKYVYIAELLAHKIHVYEK HANWTLTPLKSLDFNTLVDNISVDPETGDLWVGCHPNGMKIFFYDSENPP ASEVLRIQNILTEEPKVTQVYAENGTVLQGSTVASVYKGKLLIGTVFHKA LYCEL
Database link: P27169
- WB: Human liver tissue extracts and plasma. IHC-P: Mouse liver tissue.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 1.21% Tris, 0.75% Glycine, 20% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
Our Abpromise guarantee covers the use of ab228597 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/100 - 1/1000.|
|WB||1/500 - 1/3000. Predicted molecular weight: 40 kDa.|
FunctionHydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.
Tissue specificityPlasma, associated with HDL (at protein level). Expressed in liver, but not in heart, brain, placenta, lung, skeletal muscle, kidney or pancreas.
Involvement in diseaseGenetic variation in PON1 is associated with susceptibility to microvascular complications of diabetes type 5 (MVCD5) [MIM:612633]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Note=Homozygosity for the Leu-54 allele is strongly associated with the development of retinal disease in diabetic patients.
Sequence similaritiesBelongs to the paraoxonase family.
The signal sequence is not cleaved.
Present in two forms, form B contains a disulfide bond, form A does not.
Cellular localizationSecreted > extracellular space.
- Information by UniProt
- A esterase 1 antibody
- A-esterase 1 antibody
- Aromatic esterase 1 antibody
All lanes : Anti-PON1 antibody (ab228597) at 1/500 dilution
Lane 1 : Human plasma
Lane 2 : Human liver tissue extract
Lysates/proteins at 30 µg per lane.
Developed using the ECL technique.
Predicted band size: 40 kDa
Paraffin-embedded mouse liver tissue stained for PON1 with ab228597 at 1/500 dilution in immunohistochemical analysis.
ab228597 has not yet been referenced specifically in any publications.